Risks of breast and endometrial cancer after estrogen and estrogen–progestin replacement

Ingemar Persson(Karolinska Institutet), Elisabete Weiderpass(Karolinska Institutet), Leif Bergkvist(Karolinska Institutet), Reinhold Bergström(Karolinska Institutet), Catherine Schairer(Division of Cancer Epidemiology and Genetics)
Cancer Causes & Control
July 1, 1999
10.1023/a:1008909128110
Cited by 261

Abstract

Related Papers

EPIDEMIOLOGY OF OSTEOPOROSIS AND OSTEOPOROTIC FRACTURES
Steven R. Cummings, Jennifer L. Kelsey, Michael C. Nevitt et al.|Epidemiologic Reviews|1985|1.7k
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Malcolm C. Pike, Darcy Spicer, Laila Dahmoush et al.|Epidemiologic Reviews|1993|1k
Breast cancer screening with mammography: overview of Swedish randomised trials
L. Nyström, Stig Wall, L. E. Rutqvist et al.|The Lancet|1993|977
Hormone replacement therapy and endometrial cancer risk: A meta-analysis
Deb Grady, Tebeb Gebretsadik, Karla Kerlikowske et al.|Obstetrics and Gynecology|1995|959
Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
Shirley A.A. Beresford, Noel S. Weiss, Lynda F. Voigt et al.|The Lancet|1997|448